Immune Checkpoint Inhibition in Sepsis: A Phase 1b Randomized, Placebo-Controlled, Single Ascending Dose Study of Antiprogrammed Cell Death-Ligand 1 Antibody (BMS-936559)
Hotchkiss, Richard S, Colston, Elizabeth, Yende, Sachin, Angus, Derek C, Moldawer, Lyle L, Crouser, Elliott D, Martin, Greg S, Coopersmith, Craig M, Brakenridge, Scott, Mayr, Florian B, Park, Pauline K, Ye, June, Catlett, Ian M, Girgis, Ihab G, Grasela, Dennis M
Published in Critical care medicine (01.05.2019)
Published in Critical care medicine (01.05.2019)
Get more information
Journal Article
Immune checkpoint inhibition in sepsis: a Phase 1b randomized study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of nivolumab
Hotchkiss, Richard S., Colston, Elizabeth, Yende, Sachin, Crouser, Elliott D., Martin, Greg S., Albertson, Timothy, Bartz, Raquel R., Brakenridge, Scott C., Delano, Matthew J., Park, Pauline K., Donnino, Michael W., Tidswell, Mark, Mayr, Florian B., Angus, Derek C., Coopersmith, Craig M., Moldawer, Lyle L., Catlett, Ian M., Girgis, Ihab G., Ye, June, Grasela, Dennis M.
Published in Intensive care medicine (01.10.2019)
Published in Intensive care medicine (01.10.2019)
Get full text
Journal Article
Discovery of a Hepatitis C Virus NS5B Replicase Palm Site Allosteric Inhibitor (BMS-929075) Advanced to Phase 1 Clinical Studies
Yeung, Kap-Sun, Beno, Brett R, Parcella, Kyle, Bender, John A, Grant-Young, Katherine A, Nickel, Andrew, Gunaga, Prashantha, Anjanappa, Prakash, Bora, Rajesh Onkardas, Selvakumar, Kumaravel, Rigat, Karen, Wang, Ying-Kai, Liu, Mengping, Lemm, Julie, Mosure, Kathy, Sheriff, Steven, Wan, Changhong, Witmer, Mark, Kish, Kevin, Hanumegowda, Umesh, Zhuo, Xiaoliang, Shu, Yue-Zhong, Parker, Dawn, Haskell, Roy, Ng, Alicia, Gao, Qi, Colston, Elizabeth, Raybon, Joseph, Grasela, Dennis M, Santone, Kenneth, Gao, Min, Meanwell, Nicholas A, Sinz, Michael, Soars, Matthew G, Knipe, Jay O, Roberts, Susan B, Kadow, John F
Published in Journal of medicinal chemistry (25.05.2017)
Published in Journal of medicinal chemistry (25.05.2017)
Get full text
Journal Article
The effect of hepatic impairment on the pharmacokinetics of asunaprevir, an HCV NS3 protease inhibitor
Eley, Timothy, He, Bing, Chang, Ih, Colston, Elizabeth, Child, Michael, Bedford, William, Kandoussi, Hamza, Pasquinelli, Claudio, Marbury, Thomas C, Bertz, Richard J
Published in Antiviral therapy (2015)
Published in Antiviral therapy (2015)
Get full text
Journal Article
Mechanisms of Hyperbilirubinemia During Peginterferon Lambda-1a Therapy for Chronic Hepatitis C Infection: A Retrospective Investigation
Zwirtes, Ricardo, Narasimhan, Premkumar, Wind-Rotolo, Megan M, Xu, Dong, Hruska, Matthew W, Kishnani, Narendra, Colston, Elizabeth M, Srinivasan, Subasree
Published in Journal of interferon & cytokine research (01.11.2016)
Published in Journal of interferon & cytokine research (01.11.2016)
Get full text
Journal Article
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial
Armstrong, April W., Gooderham, Melinda, Warren, Richard B., Papp, Kim A., Strober, Bruce, Thaçi, Diamant, Morita, Akimichi, Szepietowski, Jacek C., Imafuku, Shinichi, Colston, Elizabeth, Throup, John, Kundu, Sudeep, Schoenfeld, Steve, Linaberry, Misti, Banerjee, Subhashis, Blauvelt, Andrew
Published in Journal of the American Academy of Dermatology (01.01.2023)
Published in Journal of the American Academy of Dermatology (01.01.2023)
Get full text
Journal Article
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial
Strober, Bruce, Thaçi, Diamant, Sofen, Howard, Kircik, Leon, Gordon, Kenneth B., Foley, Peter, Rich, Phoebe, Paul, Carle, Bagel, Jerry, Colston, Elizabeth, Throup, John, Kundu, Sudeep, Sekaran, Chitra, Linaberry, Misti, Banerjee, Subhashis, Papp, Kim A.
Published in Journal of the American Academy of Dermatology (01.01.2023)
Published in Journal of the American Academy of Dermatology (01.01.2023)
Get full text
Journal Article
43872 Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Scalp, Nail, and Palmoplantar Psoriasis in Japanese Patients With Plaque Psoriasis: Subset Analysis of the Phase 3 POETYK PSO-4 Trial
Imafuku, Shinichi, Okubo, Yukari, Tada, Yayoi, Ohtsuki, Mamitaro, Shao, Yanqiu, Colston, Elizabeth, Kisa, Renata M., Banerjee, Subhashis, Morita, Akimichi
Published in Journal of the American Academy of Dermatology (01.09.2023)
Published in Journal of the American Academy of Dermatology (01.09.2023)
Get full text
Journal Article
43110 Deucravacitinib, a Selective Tyrosine Kinase 2 Inhibitor, in Japanese Patients With Plaque Psoriasis: PASI Body Region and Component Scores in a Phase 3 Trial
Tada, Yayoi, Imafuku, Shinichi, Okubo, Yukari, Ohtsuki, Mamitaro, Shao, Yanqiu, Colston, Elizabeth, Napoli, Andrew, Hippeli, Lauren, Banerjee, Subhashis, Morita, Akimichi
Published in Journal of the American Academy of Dermatology (01.09.2023)
Published in Journal of the American Academy of Dermatology (01.09.2023)
Get full text
Journal Article
39861 Deucravacitinib, a Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Japanese Patients With Psoriasis: Absolute PASI Outcomes in a Phase 3 Trial
Okubo, Yukari, Imafuku, Shinichi, Tada, Yayoi, Ohtsuki, Mamitaro, Shao, Yanqiu, Colston, Elizabeth, Napoli, Andrew, Hippeli, Lauren, Banerjee, Subhashis, Morita, Akimichi
Published in Journal of the American Academy of Dermatology (01.09.2023)
Published in Journal of the American Academy of Dermatology (01.09.2023)
Get full text
Journal Article
43851 Deucravacitinib Long-term Efficacy With Continuous Treatment in Plaque Psoriasis: 2-Year Results From the Phase 3 POETYK PSO-1 and POETYK PSO-LTE Trials
Lebwohl, Mark, Warren, Richard B., Kircik, Leon, Colston, Elizabeth, Hippeli, Lauren, Napoli, Andrew, Kisa, Renata M., Banerjee, Subhashis, Menter, Alan, Thaçi, Diamant, Blauvelt, Andrew
Published in Journal of the American Academy of Dermatology (01.09.2023)
Published in Journal of the American Academy of Dermatology (01.09.2023)
Get full text
Journal Article
43887 Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Efficacy by Baseline Demographic and Disease Characteristics in the Phase 3 POETYK PSO-1 and PSO-2 Trials
Gooderham, Melinda, Spelman, Lynda, Imafuku, Shinichi, Romanelli, Marco, Merola, Joseph F., Armstrong, April W., Colston, Elizabeth, Banerjee, Subhashis, Scharnitz, Thomas, Blauvelt, Andrew
Published in Journal of the American Academy of Dermatology (01.09.2023)
Published in Journal of the American Academy of Dermatology (01.09.2023)
Get full text
Journal Article
43879 Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: 2-year Efficacy by Prior Biologic Treatment in the Phase 3 POETYK PSO Program
Warren, Richard B., Armstrong, April W., Imafuku, Shinichi, Paul, Carle, Kircik, Leon, Colston, Elizabeth, Scharnitz, Thomas, Wang, Tao, Banerjee, Subhashis, Strober, Bruce
Published in Journal of the American Academy of Dermatology (01.09.2023)
Published in Journal of the American Academy of Dermatology (01.09.2023)
Get full text
Journal Article
43827 Deucravacitinib Long-term Efficacy in Patients Originally Randomized to Placebo: 2-Year Results From the POETYK PSO Program
Lebwohl, Mark, Warren, Richard B., Imafuku, Shinichi, Bagel, Jerry, Armstrong, April W., Passeron, Thierry, Colston, Elizabeth, Hippeli, Lauren, Napoli, Andrew, Thaçi, Diamant, Blauvelt, Andrew
Published in Journal of the American Academy of Dermatology (01.09.2023)
Published in Journal of the American Academy of Dermatology (01.09.2023)
Get full text
Journal Article
Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in Japanese patients with moderate to severe plaque, erythrodermic, or generalized pustular psoriasis: Efficacy and safety results from an open‐label, phase 3 trial
Imafuku, Shinichi, Okubo, Yukari, Tada, Yayoi, Ohtsuki, Mamitaro, Colston, Elizabeth, Napoli, Andrew, Shao, Yanqiu, Banerjee, Subhashis, Morita, Akimichi
Published in Journal of dermatology (01.03.2024)
Published in Journal of dermatology (01.03.2024)
Get full text
Journal Article
Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: A subset analysis of two phase 3 randomized trials in plaque psoriasis
Blauvelt, Andrew, Rich, Phoebe, Sofen, Howard, Strober, Bruce, Merola, Joseph F., Lebwohl, Mark, Morita, Akimichi, Szepietowski, Jacek C., Lambert, Jo, Hippeli, Lauren, Colston, Elizabeth, Balagula, Eugene, Banerjee, Subhashis, Thaçi, Diamant
Published in Journal of the American Academy of Dermatology (01.04.2024)
Published in Journal of the American Academy of Dermatology (01.04.2024)
Get full text
Journal Article
34658 Deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, in patients with moderate to severe plaque psoriasis who had inadequate responses to apremilast at week 24 in the phase 3 POETYK PSO-1 and PSO-2 trials
Armstrong, April W., Warren, Richard B., Sofen, Howard, Spelman, Lynda, Leonardi, Craig, Banerjee, Subhashis, Wang, Tao, Throup, John, Colston, Elizabeth, Napoli, Andrew, Kimball, Alexa B.
Published in Journal of the American Academy of Dermatology (01.09.2022)
Published in Journal of the American Academy of Dermatology (01.09.2022)
Get full text
Journal Article
Deucravacitinib in moderate‐to‐severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO‐1 and PSO‐2)
Strober, Bruce, Blauvelt, Andrew, Warren, Richard B., Papp, Kim A., Armstrong, April W., Gordon, Kenneth B., Morita, Akimichi, Alexis, Andrew F., Lebwohl, Mark, Foley, Peter, Kisa, Renata M., Colston, Elizabeth, Wang, Tao, Banerjee, Subhashis, Thaçi, Diamant
Published in Journal of the European Academy of Dermatology and Venereology (01.08.2024)
Published in Journal of the European Academy of Dermatology and Venereology (01.08.2024)
Get full text
Journal Article
Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Efficacy by Baseline Demographic and Disease Characteristics in the Phase 3 POETYK PSO-1 and PSO-2 Trials
Gooderham, Melinda, Spelman, Lynda, Imafuku, Shinichi, Romanelli, Marco, Merola, Joseph F., Armstrong, April W., Colston, Elizabeth, Banerjee, Subhashis, Scharnitz, Thomas, Blauvelt, Andrew
Published in Skin (Milwood, N.Y.) (17.07.2023)
Published in Skin (Milwood, N.Y.) (17.07.2023)
Get full text
Journal Article